Biotech Values

[DewDiligence]

LLY’s Dulaglutide non-inferior to NVO’s Victoza in 600-patient phase-3 study:

http://finance.yahoo.com/news/lilly-weekly-diabetes-drug-succeeds-130001249.html

"Dulaglutide is the only GLP-1 agonist to show non-inferiority against liraglutide's highest-approved dose in a Phase III trial," Enrique Conterno, president of Lilly Diabetes, said in a statement.

Victoza, which owns about 70 percent of the market for GLP-1 drugs, had sales of more than $590 million in the fourth quarter, putting it on track to exceed $2 billion this year.

The trial compared the two drugs after 26 weeks. Full details (including the size of the NI margin) will be presented at an unspecified medical conference.